Certainly some of the subset data will better than what we have seen so far, so there is little chance of this being a washout.
So what? This type of subset analysis is not useful for approval, and therefore won't bring in the $$$, making ARIA less attractive. Also, efficacy in a hypothetical subset X *limits* the drug's utility because it also says you can not give this drug to subset Y and Z.
If some unfavorable Rida data is found, and Merck confirms the combo strength of Rida in its other trials, and of course, who wouldn't want Pona, I could see Mrk trying a bid on any serious weakness in ARIA.
But they've already got a big chunk of Rida through the development program. Why do they want to buy the company outright? And if they wanted ARIA for ponatinib, they would have made a bid already.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.